Related Experiment Video
Updated: May 20, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
New AMPA antagonists in epilepsy
Emilio Russo1, Rosaria Gitto, Rita Citraro
1University "Magna Graecia" of Catanzaro, School of Medicine, Science of Health Department, Catanzaro, Italy.
Expert Opinion on Investigational Drugs
|July 14, 2012
Summary
New antiepileptic drugs targeting AMPA receptors (AMPARs) show promise for refractory epilepsy. Despite past challenges with pharmacokinetics and tolerability, newer agents like perampanel offer improved efficacy and safety for seizure management.
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Epilepsy affects many, with limited treatment options due to refractory seizures and antiepileptic drug (AED) side effects.
- Glutamate's primary excitatory neurotransmitter role and AMPA receptors (AMPARs) are key targets for AED development, implicated in seizures and neurodegeneration.
- Research into AMPAR ligands has yielded both competitive and noncompetitive antagonists.
Purpose of the Study:
- To review the architecture and structure-activity relationships of AMPA receptor antagonists.
- To summarize the efficacy of AMPAR antagonists in preclinical models and human clinical trials for epilepsy.
- To highlight advances in the development of AMPAR antagonists for epilepsy treatment.
Main Methods:
- Review of scientific literature on AMPA receptor antagonists.
- Analysis of structure-activity relationships of antagonist molecules.
- Evaluation of preclinical and clinical trial data for AMPAR antagonists in epilepsy.
Main Results:
- Detailed description of AMPA receptor antagonist architecture and structure-activity relationships.
- Evidence of AMPAR antagonist effects in preclinical epilepsy models.
- Data from clinical trials assessing AMPAR antagonists in epileptic patients.
Conclusions:
- AMPA receptor antagonists demonstrate significant clinical potential for epilepsy treatment.
- Past limitations in pharmacokinetics and tolerability have hindered clinical application.
- Newer drugs, such as perampanel, show improved pharmacokinetic profiles and tolerability, justifying clinical use due to efficacy.
More Related Videos
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...